Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | HTR6 | P50406 | 3/20 | 0.44 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3952442 | 0.85 | HTR6 (0.61) | HTR6HTR2B | |
| SCHEMBL3957243 | 0.78 | HTR6 (0.48) | HTR6MAPTRXFP1MEN1KMT2A | |
| SCHEMBL3833987 | 0.71 | GRM5 (0.58) | GRM5POLBMAPTMEN1KMT2A | |
| SCHEMBL3956924 | 0.71 | HTR6 (0.54) | HTR6 | |
| SCHEMBL3528627 | 0.69 | TDP1 (0.47) | POLBHTR6MEN1KMT2ATSHR | |
| SCHEMBL19570982 | 0.68 | PKM (0.64) | GRM5POLBHTR6FFAR2MAPT | |
| SCHEMBL13677019 | 0.66 | GRM5 (0.71) | GRM5HTR6MAPTCES2THRB | |
| SCHEMBL19284664 | 0.66 | TSHR (0.59) | HTR6MAPTMEN1KMT2APKM | |
| SCHEMBL3531502 | 0.65 | HASPIN (0.39) | HTR6 | |
| SCHEMBL3535823 | 0.65 | HTR6 (0.50) | HTR6GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232618-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-04 | — | — | US | claimed |
| CN-1771244-A | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2006-05-10 | — | — | CN | claimed |
| US-20040167122-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH | 2004-08-26 | — | — | US | claimed |
| US-20090253711-A1 | HETEROCYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2009-10-08 | — | — | US | disclosed |
| US-7560470-B2 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-07-14 | — | — | US | disclosed |
| CN-100422171-C | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2008-10-01 | — | — | CN | disclosed |
| US-20070232618-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-04 | — | — | US | disclosed |
| US-7238696-B2 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-07-03 | — | — | US | disclosed |
| CN-1771244-A | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2006-05-10 | — | — | CN | disclosed |
| US-20040167122-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232618-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR2C, HTR3B | GRM5 46/4885POLB 4874/4885HTR6 1/4885 |
| US-20090253711-A1 | HETEROCYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR2C, HTR3B | GRM5 46/4885POLB 4874/4885HTR6 1/4885 |
| US-20040167122-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR1A, HTR2C | GRM5 47/4885POLB 4874/4885HTR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.